Cardiopulmonary bypass is associated with early allograft dysfunction but not death after double-lung transplantation

被引:77
作者
Gammie, JS [1 ]
Lee, JC [1 ]
Pham, SM [1 ]
Keenan, RJ [1 ]
Weyant, RJ [1 ]
Hattler, BG [1 ]
Griffith, BP [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Div Cardiothorac Surg, Pittsburgh, PA 15213 USA
关键词
D O I
10.1016/S0022-5223(98)70396-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To assess the effect of cardiopulmonary bypass on allograft function and recipient survival in double-lung transplantation. Methods: Retrospective review of 94 double-lung transplantations. Results: Cardiopulmonary bypass was used in 37 patients (CPB); 57 transplantations were accomplished without bypass (no-CPB), Bypass was routinely used for patients with pulmonary hypertension (n = 27) and for two recipients undergoing en bloc transplantation. Cardiopulmonary bypass was required in eight (12.3%) of the remaining 65 patients, Mean ischemic time was longer in the CPB group (346 vs 315 minutes, p = 0.04). The CPB group required more perioperative blood (11.4 vs 6.0 units, p = 0.01), Allograft function, assessed by the arterial/alveolar oxygen tension ratio, was better in the no-CPB group at 12 and 24 hours after operation (0.54 vs 0.39 at 12 hours, p = 0.002; and 0.63 vs 0.38 at 24 hours, p = 0.001), The CPB group had more severe pulmonary infiltrates at both 1 and 24 hours (p = 0.005), Diffuse alveolar damage was more common in the CPB group (69% vs 35%, p = 0.002), Median duration of intubation was longer in the CPB group (10 days) than in the no-CPB group (2 days, p = 0.002), The 30-day mortality rate (13.5% vs 7.0% in the CPB and no-CPB groups) and 1-year survival (65% vs 67%, CPB and no-CPB) were not significantly different, Conclusions: In the absence of pulmonary hypertension, cardiopulmonary bypass is only occasionally necessary in double-lung transplantation. Bypass is associated with substantial early allograft dysfunction after transplantation.
引用
收藏
页码:990 / 995
页数:6
相关论文
共 18 条
[1]   EFFECT OF CARDIOPULMONARY BYPASS ON EARLY GRAFT DYSFUNCTION IN CLINICAL LUNG TRANSPLANTATION [J].
AEBA, R ;
GRIFFITH, BP ;
KORMOS, RL ;
ARMITAGE, JM ;
GASIOR, TA ;
FUHRMAN, CR ;
YOUSEM, SA ;
HARDESTY, RL .
ANNALS OF THORACIC SURGERY, 1994, 57 (03) :715-722
[2]   INFLAMMATORY RESPONSE TO CARDIOPULMONARY BYPASS [J].
BUTLER, J ;
ROCKER, GM ;
WESTABY, S .
ANNALS OF THORACIC SURGERY, 1993, 55 (02) :552-559
[3]  
DEHOYOS A, 1993, J THORAC CARDIOV SUR, V106, P787
[4]   RELEASE OF VASOACTIVE SUBSTANCES DURING CARDIOPULMONARY BYPASS [J].
DOWNING, SW ;
EDMUNDS, LH .
ANNALS OF THORACIC SURGERY, 1992, 54 (06) :1236-1243
[5]   IMPROVED RESULTS OF LUNG TRANSPLANTATION FOR PATIENTS WITH CYSTIC-FIBROSIS [J].
EGAN, TM ;
DETTERBECK, FC ;
MILL, MR ;
PARADOWSKI, LJ ;
LACKNER, RP ;
OGDEN, WD ;
YANKASKAS, JR ;
WESTERMAN, JH ;
THOMPSON, JT ;
WEINER, MA ;
CAIRNS, EL ;
WILCOX, BR .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 109 (02) :224-235
[6]  
FRANCALANCIA NA, 1994, J HEART LUNG TRANSPL, V13, P498
[7]  
GRIFFITH BP, 1990, CLIN CHEST MED, V11, P217
[8]  
GRIFFITH BP, 1994, J THORAC CARDIOV SUR, V107, P743
[9]   A DECADE OF LUNG TRANSPLANTATION [J].
GRIFFITH, BP ;
HARDESTY, RL ;
ARMITAGE, JM ;
HATTLER, BG ;
PHAM, SM ;
KEENAN, RJ ;
PARADIS, I .
ANNALS OF SURGERY, 1993, 218 (03) :310-320
[10]  
HARDESTY RL, 1993, J THORAC CARDIOV SUR, V105, P660